

REMARKS

I. Status of Claims

Claims 25, 30 and 31 are pending in the application, as the remaining claims having been canceled. Claim 25 is now amended. Claims 25, 30 and 31 stand rejected under 35 U.S.C. §102(b) over Spiers *et al.*, and evidenced by Hibi *et al.* and over Konits *et al.* in view of Malakouti *et al.* The specific grounds for rejection, and applicants' response thereto, are set out in detail below.

II. Rejections Under 35 U.S.C. §102(b)

A. Spiers

Claims 25, 30 and 31 stand rejected over Spiers *et al.* in view of Hibi *et al.* Spiers is said to teach treatment of ALL with 6-thioguanine, and Hibi is said to teach that some ALL express PTHrP.

Applicants now provide amended claim 25 for reconsideration. In that claim, a method of decreasing ***bone destruction*** in a patient is presented. The method comprises two steps: first, identifying ***a patient having metastatic bone lesion*** of a parathyroid hormone-related peptide (PTH-rP)-expressing cancer; and second, administering to the patient a compound that down-regulates PTH-rP production through inhibition of the PTH-rP promoter, thereby decreasing bone destruction, wherein said compound is OSW3 or OSW6. Applicants submit that no bone metastases are diagnosed or treated in the report of Spiers. Reconsideration and withdrawal of the rejection is therefore respectfully requested.

B. Konits

Claims 25, 30 and 31 stand rejected over Konits *et al.* in view of Malakouti *et al.* Konits is said to teach treatment of colorectal cancer with 6-thioguanine, and Malakouti is said to teach that adenocarcinoma of the colon express PTHrP.

Applicants now provide amended claim 25 for reconsideration. In that claim, a method of decreasing ***bone destruction*** in a patient is presented. The method comprises two steps: first, identifying ***a patient having metastatic bone lesion*** of a parathyroid hormone-related peptide


(PTH-rP)-expressing cancer; and second, administering to the patient a compound that down-regulates PTH-rP production through inhibition of the PTH-rP promoter, thereby decreasing bone destruction, wherein said compound is OSW3 or OSW6. Applicants submit that no bone metastases are diagnosed or treated in the report of Konits. Reconsideration and withdrawal of the rejection is therefore respectfully requested.

III. Conclusion

In light of the foregoing, applicants respectfully submit that all claims are in condition for allowance, and an early notification to that effect is earnestly solicited. The examiner is invited to contact the undersigned at the telephone number listed below with any questions, comments or suggestions relating to the referenced patent application.

Please date stamp and return the enclosed postcard as evidence of receipt.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 536-3184

Date: August 26, 2005